Key terms
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CLSD news
Apr 16
7:32am ET
Clearside Biomedical Welcomes Anthony Gibney to Board
Apr 16
7:14am ET
Clearside Biomedical appoints Gibney to board of directors
Mar 18
7:07am ET
Clearside Biomedical appoints Chong as Chief Medical Officer
Mar 14
6:27am ET
Clearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial Progress
Mar 14
2:01am ET
Navigating a Regulatory Maze: Clearside Biomedical’s Challenge with Global Compliance and Anti-Corruption Laws
Mar 13
6:30am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR) and Clearside Biomedical (CLSD)
Mar 13
6:17am ET
Buy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong Financials
Mar 13
12:30am ET
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)
Mar 06
11:25am ET
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 200%, Say Analysts
Feb 09
5:13am ET
Clearside Biomedical Announces Registered Direct Offering Pricing
Feb 09
5:13am ET
Clearside Biomedical Launches $15M Direct Offering
Feb 07
8:17am ET
Clearside to sell 11.11M shares at $1.35 in registered direct offering
Jan 22
1:31pm ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Vor Biopharma (VOR) and Clearside Biomedical (CLSD)
No recent press releases are available for CLSD
CLSD Financials
Key terms
Ad Feedback
CLSD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CLSD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range